host immunomodulator drugs

Question 1

TOCILIZUMAB

Answer 1

• Humanised mAB which inhibits interleukin 6 mediated signalling by blocking IL6 from binding to receptors
• Given via intravenous infusion every 4 weeks
• Subcutaneous injection once weekly
• IMPROVED – clinical symptoms and stopped deterioration of severe COVID19

Question 2

DEXAMETHASONE

Answer 2

• Glucocorticoid drug which has good inhibitory effect on inflammatory factors
• Eye drop – 4-6 times a day
• Decreases inflammatory responses
• Increases conc of glucose levels
• Raised BP

Question 3

DEXAMETHASONE

Clinical data

Answer 3

• In patients hospitalised with COVIID-19 dexamethasone resulted in lower 28-day mortality among those who were receiving who were receiving oxygen alone at randomisation